• D Aguillon, P Seguin, and Y Mallédant.
• Département d'anesthésie-réanimation 1, réanimation chirurgicale, centre hospitalier régional Pontchaillou, 2, rue Henri-Le-Guilloux, 35033 Rennes cedex, France.
• Ann Fr Anesth Reanim. 2003 Jan 1; 22 (1): 30-8.

ObjectivesData synthesis on physiopathology and treatment of hepatorenal syndrome (HRS).Data SourcesData were searched in the Medline database from 1975 to 2002 using the following key-words: hepatorenal syndrome, ascite, cirrhosis and portal hypertension.Data ExtractionPublications from 1986 to 2002 were selected depending on the quality of their methodology and their pertinence. One publication from 1975 was kept.Data SynthesisHepatorenal syndrome is a common and severe complication of patients with advanced liver cirrhosis with ascites. It is a functional renal failure due to intense vasoconstriction of the renal circulation secondary to an intense splanchnic vasodilatation. Two types of HRS are differentiated mainly by the speed and the magnitude of the renal failure. Liver transplantation remains the best treatment but is rarely applicable because of the short survival after diagnosis. In the last few years, new therapy have been developed, vasoconstrictor drugs which mainly elicit their effects on the splanchnic circulation as vasopressin and principally its analogues ornipressine and terlipressine are effective in improving renal function and could act as bridge for liver transplantation. The place of the transjugular intrahepatic portosystemic shunt remain to be evaluated.ConclusionPrognosis of patients with HRS remains poor but the pharmacologic treatment by terlipressine has improved the prognosis particularly in order to wait liver transplantation.

12 keywords...

hide…